Ubiquitin proteasome-mediated protein degradation is an important process in maintaining cellular homeostasis through regulation of many important cellular processes, including differentiation, proliferation and apoptosis. Accordingly, aberrant protein degradation through this system underlies many diseases, including cancer. The mammalian target of rapamycin (mTOR), coupled with raptor and rictor to form mTOR complex 1 (mTORC1) and mTORC complex 2 (mTORC2), respectively, plays a critical role in the regulation of cell proliferation and survival. Hence, mTOR inhibitors including the conventional rapamycin and its analogues (rapalogs) and novel mTOR kinase inhibitors are either approved drugs for cancer therapy or being widely tested in clinical trials. We and other have suggested that mTOR, raptor and rictor can be degraded through a mechanism involving the E3 ubiquitin ligase FBXW7 (also called FBW7 or CDC4). However, the mechanisms underlying their degradation and the impact of degradation-mediated regulation of the mTOR axis on mTOR- targeted cancer therapy are largely unknown. In this proposal, we hypothesize that the key components in the mTOR complexes, rictor and raptor, are subjected to FBXW7-mediated and GSK3-dependent degradation. As a result, both mTORC1 and mTORC2 are regulated by the degradation mechanism. This hypothesis will be tested by accomplishing 3 aims: 1) to demonstrate FBXW7-mediated ubiquitination and proteasome degradation of raptor and rictor and its impact on the mTOR signaling;2) to determine the involvement of GSK3 in FBXW7-mediated degradation of rictor and raptor;and 3) to evaluate the impact of degradation regulation of the mTOR axis on mTOR-targeted cancer therapy. The objectives of this proposal are to understand the mechanisms through which raptor and rictor are degraded and to determine the impact of regulation of the degradation of these proteins on mTOR-targeted cancer therapy.

Public Health Relevance

The objectives of the proposal are to understand the mechanisms through which raptor and rictor are degraded and to determine the impact of regulation of the degradation of these proteins on mTOR-targeted cancer therapy. Thus, this proposal not only helps us to understand the biology of mTOR regulation by degradation, but also has great translational significance that immediately impacts clinical treatment of cancer.

Agency
National Institute of Health (NIH)
Type
Research Project (R01)
Project #
5R01CA118450-09
Application #
8699154
Study Section
Basic Mechanisms of Cancer Therapeutics Study Section (BMCT)
Program Officer
Forry, Suzanne L
Project Start
Project End
Budget Start
Budget End
Support Year
9
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Emory University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
City
Atlanta
State
GA
Country
United States
Zip Code
30322
Yao, Weilong; Oh, You-Take; Deng, Jiusheng et al. (2016) Expression of Death Receptor 4 Is Positively Regulated by MEK/ERK/AP-1 Signaling and Suppressed upon MEK Inhibition. J Biol Chem 291:21694-21702
Li, S; Oh, Y-T; Yue, P et al. (2016) Inhibition of mTOR complex 2 induces GSK3/FBXW7-dependent degradation of sterol regulatory element-binding protein 1 (SREBP1) and suppresses lipogenesis in cancer cells. Oncogene 35:642-50
Lang, Liwei; Ding, Han-Fei; Chen, Xiaoguang et al. (2015) Internal Ribosome Entry Site-Based Bicistronic In Situ Reporter Assays for Discovery of Transcription-Targeted Lead Compounds. Chem Biol 22:957-64
Koo, Junghui; Yue, Ping; Deng, Xingming et al. (2015) mTOR Complex 2 Stabilizes Mcl-1 Protein by Suppressing Its Glycogen Synthase Kinase 3-Dependent and SCF-FBXW7-Mediated Degradation. Mol Cell Biol 35:2344-55
Koo, Junghui; Wu, Xiaoyun; Mao, Zixu et al. (2015) Rictor Undergoes Glycogen Synthase Kinase 3 (GSK3)-dependent, FBXW7-mediated Ubiquitination and Proteasomal Degradation. J Biol Chem 290:14120-9
Yao, Weilong; Yue, Ping; Zhang, Guojing et al. (2015) Enhancing therapeutic efficacy of the MEK inhibitor, MEK162, by blocking autophagy or inhibiting PI3K/Akt signaling in human lung cancer cells. Cancer Lett 364:70-8
Koo, Junghui; Yue, Ping; Gal, Anthony A et al. (2014) Maintaining glycogen synthase kinase-3 activity is critical for mTOR kinase inhibitors to inhibit cancer cell growth. Cancer Res 74:2555-68
Ren, Hui; Koo, Junghui; Guan, Baoxiang et al. (2013) The E3 ubiquitin ligases β-TrCP and FBXW7 cooperatively mediates GSK3-dependent Mcl-1 degradation induced by the Akt inhibitor API-1, resulting in apoptosis. Mol Cancer 12:146
Zhao, Liqun; Yue, Ping; Khuri, Fadlo R et al. (2013) mTOR complex 2 is involved in regulation of Cbl-dependent c-FLIP degradation and sensitivity of TRAIL-induced apoptosis. Cancer Res 73:1946-57
Li, Yikun; Wang, Xuerong; Yue, Ping et al. (2013) Protein phosphatase 2A and DNA-dependent protein kinase are involved in mediating rapamycin-induced Akt phosphorylation. J Biol Chem 288:13215-24

Showing the most recent 10 out of 29 publications